Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Transcriptomic profiling of immune cells in malignant pleural effusions identifies macrophage reprogramming associated with survival
Aaditya Khatri, Huimin Wang, Zhicheng Ji, Prekshaben Patel, Smita K. Nair, Javid P. Mohammed, Beth H. Shaz, Andrew B. Nixon, Scott M. Palmer, Kamran Mahmood
Aaditya Khatri, Huimin Wang, Zhicheng Ji, Prekshaben Patel, Smita K. Nair, Javid P. Mohammed, Beth H. Shaz, Andrew B. Nixon, Scott M. Palmer, Kamran Mahmood
View: Text | PDF
Research Article Oncology Pulmonology

Transcriptomic profiling of immune cells in malignant pleural effusions identifies macrophage reprogramming associated with survival

  • Text
  • PDF
Abstract

Despite advances in treatment approaches for lung cancer, the morbidity and survival of patients with lung cancer with malignant pleural effusions (MPE) remain poor. This is in part due to gaps in understanding the role of immune cells in the pleural fluid microenvironment. We performed single-cell analysis with flow cytometry validation of CD45+ cells in 8 MPE and 5 benign pleural fluid effusion (BPE) specimens to identify changes in the transcriptomic landscape of immune cells across disease states. We found upregulation of proinflammatory signaling pathways, including IFN and TNF signaling, in T cells, B cells, and macrophages in benign compared with malignant pleural effusions. Proinflammatory HLA-DR+ macrophages were associated with good survival outcomes while protumorigenic HLA-DR– macrophages with upregulation of angiogenesis, TGF-β, and fibronectin signaling were associated with poor survival outcomes in patients with MPE. We also validated these findings with macrophage cell surface expression markers using flow cytometry in 14 MPE and 7 BPE specimens. Finally, we performed multiplex cytokine analysis, which showed enrichment of the type 3 inflammatory cytokine, IL-17A, in MPE as a putative mechanism for macrophage reprogramming. These data provide a rich resource for interrogating the immune cell types and states present across the spectrum of pleural disease. They offer not only prognostic value for patient outcomes at the time of pleural fluid collection but also insights into novel immunotherapy targets.

Authors

Aaditya Khatri, Huimin Wang, Zhicheng Ji, Prekshaben Patel, Smita K. Nair, Javid P. Mohammed, Beth H. Shaz, Andrew B. Nixon, Scott M. Palmer, Kamran Mahmood

×

Figure 5

Flow cytometry validation identifies HLA-DRlo macrophage associated with poor survival outcomes in pleural metastasis.

Options: View larger image (or click on image) Download as PowerPoint
Flow cytometry validation identifies HLA-DRlo macrophage associated with...
(A) Gating strategy used to identify immune (I) and myeloid (M) populations in 21 pleural effusion specimens (n = 7 BPE, median survival 54 months; n = 6 MPE with good prognosis; median survival 16 months; n = 8 MPE with poor prognosis, median survival 2 months). (B) Representative plots showing median fluorescence intensity (MFI) analysis of HLA-DRlo populations of myeloid cells in benign (transudative, n = 3, or exudative, n = 4) and malignant (good prognosis, n = 6, or poor prognosis, n = 8) samples. (C) Kruskal-Wallis nonparametric test showed a significant difference between HLA-DRlo myeloid populations in benign and malignant groups with P = 0.04. Post hoc Dunn’s multiple-comparison test showed a significant increase in HLA-DRlo populations in myeloid cells from patients with poor survival. (D) Mantel-Cox log-rank survival curve analysis in MPE (n = 14) showed a significant decrease in survival outcomes in patients with higher HLA-DR low myeloid cell populations. (E) Wilcoxon rank sum test was performed showing significant downregulation in HLA-DR expression in patients with poor survival in the single-cell dataset correlating with the flow cytometry results. ****P < 0.001. (F and G) Multiplex cytokine analysis of type 1 and type 3 inflammatory cytokines and VEGFA in matched pleural fluid and serum samples from benign (n = 5) and malignant (n = 10) pleural effusions showed a significant increase in IL-17A but not IL-1 and TNF in MPE compared with BPE. The data represent 1-way ANOVA with post hoc Tukey testing for multiple comparisons. There was no significant difference in any cytokine expression in matched serum samples. *P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts